Peptide Affinity Ligands for Universal IgG Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current affinity chromatography methods for monoclonal antibodies and Fc fusion proteins face challenges due to the limitations of bacterial immunoglobulin-binding proteins, including incomplete binding of human IgG subclasses, high costs, contamination risks, and harsh elution conditions that can impact the immunogenicity and stability of recombinant antibodies.
Innovation Solution
Development of specific short linear peptide affinity ligands with tailored structures for binding to immunoglobulins, which can be covalently coupled to solid supports for immobilization and used in multimeric forms to enhance binding affinity and stability, allowing for mild interaction conditions and improved purification and detection processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bacterial immunoglobulin-binding proteins (Protein A or Protein G) are used as affinity ligands, then high specificity and selectivity are achieved, but the binding coverage is incomplete (e.g., Protein A does not bind all human IgG subclasses including IgG3)
Solution Approach 1:
The patent creates a universal affinity ligand system that binds all human IgG subclasses (IgG1, IgG2, IgG3, IgG4) through a single peptide sequence or ligand structure, eliminating the need for subclass-specific ligands. This multi-functional approach allows one ligand to perform the binding function across all IgG variants, resolving the contradiction between specificity and universal coverage.
Solution Approach 2:
The patent modifies the ligand structure from bacterial proteins to short synthetic peptides with specific amino acid sequences that exhibit altered binding parameters. These peptide ligands have different binding characteristics that enable them to interact with all IgG subclasses, changing the binding parameters from subclass-specific to universally applicable while maintaining high affinity.
2Reliability
If bacterial immunoglobulin-binding proteins are used as affinity ligands, then high binding affinity is achieved, but the cost increases and contamination risks arise due to bacterial isolation requirements
Solution Approach 1:
The patent replaces expensive, complex bacterial proteins with inexpensive synthetic peptide ligands that can be produced through simple chemical synthesis. These short peptide sequences are economically manufacturable without requiring bacterial culture, isolation, and purification processes, thereby eliminating contamination risks and reducing production costs while maintaining binding functionality.
Solution Approach 2:
The patent substitutes the biological system (bacterial protein expression and isolation) with a chemical synthesis system. Instead of using complex biological machinery to produce affinity ligands, the invention employs chemical peptide synthesis methods, replacing the mechanical/biological production process with a simpler chemical approach that avoids contamination and reduces cost.
3Productivity
If affinity chromatography based on protein A or protein G columns is used, then rapid turnaround time and simplicity are achieved, but harsh elution conditions are required that can negatively impact antibody structure and function
Solution Approach 1:
The patent changes the elution conditions by using peptide ligands that allow mild elution at physiological or near-physiological pH values, unlike Protein A/G which require harsh acidic conditions. This parameter change in elution pH and stringency maintains antibody structure and function while achieving rapid purification throughput.
Solution Approach 2:
The patent introduces synthetic peptide ligands as intermediary binding agents between the antibody and the chromatography matrix. These peptide intermediaries provide a gentler binding interface that allows for mild elution conditions, mediating the interaction in a way that preserves antibody integrity while enabling rapid purification cycles.
4Reliability
If bacterial immunoglobulin-binding proteins are used as affinity ligands, then high selectivity is achieved, but column shelf life is reduced due to ligand instability under elution and sanitization conditions
Solution Approach 1:
The patent employs stable synthetic peptide ligands that are resistant to degradation under harsh elution and sanitization conditions. These peptide ligands maintain their structural integrity and binding selectivity over extended periods, enabling columns to withstand repeated cleaning cycles and maintain functionality, thereby extending column shelf life while preserving selectivity.
Solution Approach 2:
The patent creates a composite affinity ligand system combining synthetic peptide sequences with stable chemical structures that resist denaturation and degradation. This composite approach integrates the selectivity of immunoglobulin-binding peptides with the stability of synthetic polymers or chemically modified structures, resulting in a material that maintains both selectivity and long-term durability under challenging conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide ligands provide efficient and cost-effective purification and detection of immunoglobulins and Fc-fusion proteins, maintaining antibody stability and reducing immunogenicity concerns, while enabling the formation of multimeric complexes for enhanced binding and therapeutic applications.
Implementation Method 1
affinity ligands having binding affinity for immunoglobulins
Implementation Method 2
peptide affinity ligands with unique structures were identified from chemical libraries and engineered using different molecular display methodologies
Data Source
AI summary
The present invention relates to ligand that may be a peptide compound as well as peptoid or retro-inverso analogues thereof with binding affinity for the Fc region of immunoglobulins. The invention further relates to the application of such peptides and variants thereof for purification of immunoglobulins on the basis of affinity chromatography, non-covalent antibody labelling, antibody detection or immobilization of antibodies to solid support.